Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9877)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

The Board is pleased to announce the unaudited consolidated interim results of the Group for the six months ended 30 June 2026, together with the comparative figures for the six months ended 30 June 2025 as follows. The unaudited consolidated financial statements of the Group for the Reporting Period have been reviewed by the management of the Company together with the Audit Committee.

FINANCIAL HIGHLIGHTS

	Six months ended 30 June		Period-to-period
	2026	2025	change
	RMB'000	*RMB'000*	*(%)*
	(unaudited)	(unaudited)	
Revenue	**64,131**	13,426	377.7%
Other income and gains	**9,833**	12,144	(19.0%)
Loss for the period	**(48,763)**	(170,289)	(71.4%)
Adjusted non-IFRS loss for the period	**(24,586)**	(91,756)	(73.2%)

The Group continues to advance its development strategy of global commercialization for its structural heart disease intervention products. For the six months ended 30 June 2026, the Group recorded revenue of RMB64.1 million, with a period-to-period growth of 377.7% and a gross profit margin of 86.5%. Our other income and gains amounted to approximately RMB9.8 million, resulting in total revenue and other income and gains of approximately RMB73.9 million, representing an increase of 189.8% as compared with the same period last year. The pace of the Group's global commercialization continued to accelerate, driving rapid expansion in revenue scale and progressively establishing a diversified and sustainable growth engine.

The purpose of the adjusted non-IFRS loss for the period is to provide supplementary information for evaluating the Group's operational performance by deducting the impacts related to share-based compensation expenses and foreign exchange fluctuations. Adjusted non-IFRS loss for the six months ended 30 June 2026 was RMB24.6 million compared to RMB91.8 million for the six months ended 30 June 2025, representing a decrease of RMB67.2 million, narrowing by 73.2% period-to-period. The decrease in adjusted non-IFRS loss was primarily attributed to revenue growth and an increased gross profit contribution, and the Group's refined operations and enhanced expense control.

BUSINESS OVERVIEW

During the Reporting Period, the Group remained focused on the structural heart disease interventional products and firmly implemented its internationalization strategy to continuously advance the clinical application and commercialization of its core technologies in the global market through a diversified core product pipeline. Following the commencement of its first year of commercialization in 2025, the Group's commercialization capabilities continued to deliver on its commercial potential. Domestic sales of its core product Ken-Valve steadily scaled up, coupled with fee-based clinical implants of multiple products across various overseas countries, driving a substantial increase in operating revenue during the period. As the global registration and commercialization network continues to expand, the Group is expected to sustain its rapid revenue growth trajectory and lay a solid foundation for its long-term sustainable development.

1. LuX-Valve Plus (Transvenous Tricuspid Valve Replacement System): Continued breakthroughs in global registration and orderly advancement of overseas commercialization

LuX-Valve Plus is the world's second approved transcatheter orthotopic tricuspid valve replacement product. During the Reporting Period, the global registration process of LuX-Valve Plus achieved further significant progress, with sustained improvements to its integrated global market footprint. LuX-Valve Plus has obtained regulatory approvals in various countries and regions. As of the date of this announcement, global cumulative implants of the LuX-Valve series products have exceeded 1,000 units, with a record of the longest follow-up of over 6 years.

In Europe, LuX-Valve Plus has successfully obtained EU MDR CE certification, not only signalling its official commencement of commercialization in the European region, but also further driving the continued rollout of its commercialization in other CE certification-covered jurisdictions;

In the United States, the pivotal randomized controlled clinical trial, which received unconditional FDA IDE approval, is progressing smoothly, with the first batch of implantation completed. This head-to-head multi-center study will further consolidate the product's evidence base and support the accessibility to the U.S. market;

In the Asia-Pacific region, LuX-Valve Plus has obtained registration approval in New Zealand, while registration submissions in additional countries continue to advance. In China, the NMPA registration review is progressing in an orderly manner. Leveraging its inclusion in the Medical Device Catalog of Hong Kong-Macao Medicine and Equipment Connect, it continues to deployed for commercial clinical application in the Greater Bay Area, ranking it among the earlier innovative devices in China to achieve commercialization for this indication.

The Group continues to leverage global multicenter clinical studies to present positive clinical data at top-tier international academic platforms. Long-term follow-up results from a series of TRINITY studies have been continuously presented at major academic conferences including EuroPCR, TCT, and PCR London Valves, consistently validating the product's overall safety and efficacy, particularly underscoring its unique advantages in large-annulus and complex-anatomy cases. The Group will continue to build on its long-accumulated technological strengths in tricuspid valve interventional diagnosis and treatment to accelerate commercialization across multiple countries to solidify its leading position in the global transcatheter tricuspid valve replacement field.

2. Ken-Valve (Transcatheter Aortic Valve Replacement System): Continued scaling of domestic commercialization and accelerated global presence

As a differentiated TAVR product covering aortic regurgitation (AR) and combined stenosis indications, Ken-Valve has entered a stage of steady growth in domestic commercialization. Supported by a multi-tiered sales network characterized by "core hospitals leading, regional centers supporting, and primary-level medical institutions coordinating," and further empowered by "Jenscare Academy (健世學苑)", an integrated online-and-offline academic promotion platform, the scale of product implants has steadily increased.

Overseas expansion continues to deliver phased milestones: following registration approval in New Zealand in February 2026, Ken-Valve obtained further approval from the Department of Health of Hong Kong during the Reporting Period, further expanding its commercial footprint in the Hong Kong, China market. As the Group continues to conduct in-depth commercial activities in multiple overseas countries and steadily advance paid overseas implants, its overseas business is set to enter a stage of deep market penetration, continuously unlocking the value of its overseas business.

During the Reporting Period, multiple mid- to long-term clinical follow-up datasets for Ken-Valve were continuously presented at leading academic conferences both domestically and internationally, fully validating its procedural convenience as well as its stability and safety in managing complex cases for large annulus patients, thereby continuously providing robust evidence-based support for market expansion at home and abroad.

Looking ahead, in the domestic market, the Group will continue to deepen channel penetration and expand coverage of medical institutions to consolidate its market advantages. In global markets, building on the approvals in New Zealand and Hong Kong, China as strategic anchors, the Group will mobilize global key clinical expert resources to drive its overseas business from single-site implants toward large-scale rollout, accelerating the implementation of its globalization strategy.

3. JensClip (Transcatheter Mitral Valve Repair Clip System): Dual-track advancement of domestic and overseas registration, with differentiated clinical advantages gaining global recognition

During the Reporting Period, the global registration of JensClip advanced steadily. The NMPA registration application is currently at a critical review stage and is expected to achieve a domestic commercial launch. Meanwhile, the CE certification registration application continues to progress, and upon approval will formally open the gateway to global developed markets.

JensClip features a unique claw-wedge mechanical locking design that enables stable multi-angle grasping, effectively reducing leaflet tension and reducing mitral regurgitation. The product's one-year follow-up data and application experience in complex, high-difficulty cases have been successively presented at domestic and international conferences, with its outstanding safety, efficacy, and procedural convenience garnering widespread attention and recognition from global clinical experts. The Group continues to develop a global KOL collaboration network and conduct systematic academic cultivation centered on the product's differentiated technical features. Upon obtaining domestic and overseas regulatory approvals, JensClip will rapidly launch commercialization to create a new revenue growth curve for the Group and further complete its full-indication product portfolio for structural heart disease intervention.

4. Continued deep cultivation of innovative R&D, optimization of the operational system, and consolidation of the foundation for long-term global development

The Group adheres to independent innovative R&D as its core driving force, continuously improving its comprehensive interventional product matrix covering tricuspid, aortic, and mitral valve diseases, and developing a product pipeline with global competitiveness. Addressing unmet clinical needs worldwide, the Group continues to iterate and optimize its existing core products while simultaneously advancing the R&D and clinical translation of multiple cutting-edge innovative pipelines to enrich its therapeutic solutions.

At the operational level, the Group sustains efforts to elevate its management effectiveness and strengthen internal operational efficiency, while precisely aligning with country-specific regulatory requirements in global multi-region registration and clinical practices. In terms of capability building, the Group continues to upgrade its R&D processes, quality management systems, and large-scale manufacturing capabilities to enhance supply chain resilience. Meanwhile, benchmarking against international standards, the Group advances its global patent portfolio and intellectual property protection system, providing comprehensive support for commercial expansion and underpinning the Group's long-term and stable development.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2026

	Notes	**2026** ***RMB'000*** **(Unaudited)**	2025 *RMB'000* (Unaudited)
Revenue	*5*	**64,131**	13,426
Cost of sales of goods		**(8,650)**	(1,599)
Gross Profit		**55,481**	11,827
Other income and gains		**9,833**	12,144
Research and development expenses		**(52,576)**	(88,885)
Administrative expenses		**(33,626)**	(57,433)
Selling and distribution expenses		**(22,470)**	(3,844)
Reversal of impairment losses on financial assets, net		**427**	321
Other expenses		**(5,163)**	(44,281)
Finance costs		**(669)**	(138)
LOSS BEFORE TAX	*6*	**(48,763)**	(170,289)
Income tax expenses	*7*	**–**	–
LOSS FOR THE PERIOD		**(48,763)**	(170,289)
OTHER COMPREHENSIVE (LOSS)/INCOME			
Other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of foreign operations		**(5,921)**	6,762
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX		**(5,921)**	6,762
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD		**(54,684)**	(163,527)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME(CONTINUED)

For the six months ended 30 June 2026

	Note	**2026** ***RMB'000*** **(Unaudited)**	2025 *RMB'000* (Unaudited)
Loss attributable to:			
Owners of the parent		**(48,690)**	(169,565)
Non-controlling interests		**(73)**	(724)
		(48,763)	(170,289)
Total comprehensive loss attributable to:			
Owners of the parent		**(54,611)**	(162,803)
Non-controlling interests		**(73)**	(724)
		(54,684)	(163,527)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	*9*		
Basic and diluted			
– For loss for the period		**RMB(0.11)**	RMB(0.41)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2026

	Notes	**30 June 2026** ***RMB'000*** **(Unaudited)**	31 December 2025 *RMB'000* (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment	*10*	**178,497**	164,390
Other intangible assets		**5,968**	5,191
Right-of-use assets		**26,003**	27,325
Time deposits		**73,381**	72,559
Other non-current assets		**8,269**	6,158
Total non-current assets		**292,118**	275,623
CURRENT ASSETS			
Inventories		**42,661**	27,115
Trade receivables	*11*	**27,608**	6,842
Prepayments, other receivables and other assets		**64,676**	59,247
Financial assets at fair value through profit or loss		**13,486**	20,000
Cash and cash equivalents		**401,132**	507,405
Total current assets		**549,563**	620,609
CURRENT LIABILITIES			
Trade payables	*12*	**21,028**	25,150
Other payables and accruals		**46,761**	50,596
Interest-bearing bank and other borrowings		**9,323**	28,041
Lease liabilities		**1,656**	2,084
Total current liabilities		**78,768**	105,871
NET CURRENT ASSETS		**470,795**	514,738
TOTAL ASSETS LESS CURRENT LIABILITIES		**762,913**	790,361

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)
As at 30 June 2026

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
NON-CURRENT LIABILITIES		
Lease liabilities	**834**	1,473
Interest-bearing bank loans	**27,877**	15,762
Total non-current liabilities	**28,711**	17,235
Net assets	**734,202**	773,126
EQUITY		
Equity attributable to owners of the parent		
Share capital	**417,167**	417,167
Treasury shares	**(3,621)**	(360)
Reserves	**337,013**	372,603
	750,559	789,410
Non-controlling interests	**(16,357)**	(16,284)
Total equity	**734,202**	773,126

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

For the six months ended 30 June 2026

1 CORPORATE AND GROUP INFORMATION

Jenscare Scientific Co., Ltd. (the "**Company**") was incorporated in the People's Republic of China (the "**PRC**") on 8 November 2011 as a limited liability company. On 23 March 2021, the Company was converted into a joint stock company with limited liability under the Company Law of the PRC. The registered office of the Company is located at No. 777 Binhai Fourth Road, Hangzhou Bay New District, Ningbo, Zhejiang, the PRC.

The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 10 October 2022.

During the period, the Company and its subsidiaries (the "**Group**") were mainly engaged in the sales, research and development of interventional products for the treatment of structural heart diseases and other related medical products.

2 BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025. This interim condensed consolidated financial information is presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand except when otherwise indicated.

3 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The International Accounting Standards ("**IASs**") Board has issued a number of amendments to International Financial Reporting Standards ("**IFRSs**") that are first effective for the current accounting period of the Group. None of these developments have a material effect on how the Group's results and financial position for the current or prior periods have been prepared or presented in the interim financial report. IFRSs comprise International Financial Reporting Standards, IASs and Interpretations.

Amendments to IFRS 9 and IFRS 7	*Amendments to the Classification and Measurement of Financial Instruments*
Amendments to IFRS 9 and IFRS 7	*Contracts Referencing Nature-dependent Electricity*
Annual Improvements to IFRS Accounting Standards – Volume 11	*Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7*

The nature and impact of the amended IFRS Accounting Standards are described below:

(a) Amendments to IFRS 9 and IFRS 7 Amendments to the Classification and Measurement of Financial Instruments clarify that a financial asset is derecognised when the entity's rights to the contractual cash flows expire or are transferred, while a financial liability is derecognised on the settlement date. The amendments introduce an accounting policy option to derecognise a financial liability that is settled through an electronic payment system before the settlement date if specified criteria are met. The amendments clarify how to assess the contractual cash flow characteristics of financial assets with environmental, social and governance and other similar contingent features. Moreover, the amendments clarify the requirements for classifying financial assets with non-recourse features and contractually linked instruments. The amendments also include additional disclosures for investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features. Since the Group's accounting policy for the derecognition of financial assets and liabilities in prior years aligned with the amendments and the Group did not have the financial assets that were addressed by the amendments, the amendments did not have any impact on the interim condensed consolidated financial information. The Group will provide additional disclosures for its equity investments designated at fair value through other comprehensive income in the Group's consolidated financial statements for the year ending 31 December 2026.

(b) Amendments to IFRS 9 and IFRS 7 Contracts Referencing Nature-dependent Electricity clarify the application of the "own-use" requirements for in-scope contracts and amend the designation requirements for a hedged item in a cash flow hedging relationship for in-scope contracts. The amendments also include additional disclosures that enable users of financial statements to understand the effects these contracts have on an entity's financial performance and future cash flows. As the Group did not have any contracts that are in the scope of the amendments, the amendments did not have any impact on the interim condensed consolidated financial information.

(c) Annual Improvements to IFRS Accounting Standards–Volume 11 set out narrow scope amendments to IFRS 1, IFRS 7 (and the accompanying Guidance on implementing IFRS 7), IFRS 9, IFRS 10 and IAS 7. The amendments include clarifications, simplifications, corrections or changes to improve consistency in the corresponding IFRS Accounting Standards. The amendments did not have any impact on the interim condensed consolidated financial information.

4 OPERATING SEGMENT INFORMATION

For management purposes, the Group is not organised into business units based on their products and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

Geographical information

(a) Revenue from external customers

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Chinese Mainland	**34,645**	2,823
Other countries/regions	**29,486**	10,603
Total revenue	**64,131**	13,426

(b) Non-current assets

Since nearly all of the Group's non-current assets were located in Chinese Mainland during the reporting period, no further geographical segment information is presented.

5 REVENUE

Revenue from sales of interventional products is recognised when control of the products has transferred, being when the goods have been shipped to the specific location and accepted by customers, or the Group has objective evidence that all criteria for acceptance have been satisfied.

A contract liability is recognised for the Group's obligation to transfer goods to customers for which the Group has received considerations (or an amount of consideration is due) from the customers. Contract liabilities as of 30 June 2026 amounting to RMB1,024,000 (31 December 2025: RMB6,514,000) is recognised.

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from sales of goods		
– at a point in time	**64,131**	13,426

6 LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/(crediting):

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Cost of inventories sold*	**8,650**	1,599
Depreciation of items of property, plant and equipment**	**7,716**	3,705
Amortisation of intangible assets	**379**	284
Depreciation of right-of-use assets	**1,304**	1,078
Research and development expenses	**52,576**	88,885
Loss on disposal of items of property, plant and equipment	**7**	18
Reversal of impairment losses on financial assets, net	**(427)**	(321)
Impairment of property, plant and equipment	**–**	292
(Reversal)/Write-down of inventories to net realisable value	**(242)**	669
Auditor's remuneration	**600**	600
Government grants	**(3,479)**	(3,022)
Bank interest income	**(5,639)**	(7,197)
Lease payments not included in the measurement of lease liabilities	**506**	623
Fair value gains, net:		
Financial assets at fair value through profit or loss	**(479)**	(1,216)
Foreign exchange differences, net	**5,156**	6,782

* The amounts disclosed for cost of inventories sold included write-down of inventories to net realisable value.

** The depreciation of property, plant and equipment and depreciation of right-of-use assets is included in "Cost of sales", "Administrative expenses", "Research and development expenses" and "Selling and distribution expenses" in the interim condensed consolidated statements of profit or loss and other comprehensive income.

7 INCOME TAX

The Group's principal applicable taxes and tax rates are as follows:

(a) Pursuant to the Corporate Income Tax Law of the PRC (the "**CIT Law**") and the respective regulations, the applicable tax rate of the Company and its subsidiaries in Chinese Mainland is 25%. No provision for Chinese Mainland income tax was made as the Group's entities in the PRC had no estimated assessable profits during the period.

(b) No provision for Hong Kong profit tax has been made at a rate of 16.5% as the Group's entity in Hong Kong has no estimated assessable profits during the period presented in the interim condensed consolidated financial information.

(c) No provision for Netherlands income tax has been made at a rate of 25.8% as the Group's entity in the Netherlands has no estimated assessable profits during the period presented in the interim condensed consolidated financial information.

(d) No provision for United States income tax was made at a rate of 29.8% as the Group's entity in the United States had no estimated assessable profits during the period.

Deferred tax assets have not been recognised in respect of these losses as it is not considered probable that taxable profits will be available against which the tax losses can be utilised.

8 DIVIDENDS

No dividend was paid or declared by the Company during the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

9 LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amount is based on the loss for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 425,243,000 (six months ended 30 June 2025: 408,934,000) in issue during the period.

The Group had potential dilutive shares throughout the period related to the shares held for the share compensation plan. Due to the Group's negative financial results during the period, shares held for the share compensation plan have an anti-dilutive effect on the Group's loss per share. Thus, the diluted loss per share is equivalent to the basic loss per share.

As of 30 June 2026, the Company has purchased its shares on the Stock Exchange at a total consideration of HK$3,701,000 (equivalent to approximately RMB3,261,000). The purchased shares will be used as award shares for the selected participants of a share award scheme. Since then, the weighted average number of such shares considered as treasury shares has been included in the calculation of basic loss per share.

The calculations of basic and diluted losses per share are based on:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss		
Loss attributable to ordinary equity holders of the parent, used in the basic and diluted loss per share calculations	**(48,690)**	(169,565)

	For the six months ended 30 June	
	2026	2025
Number of shares		
Weighted average number of ordinary shares in issue during the period used in the basic and diluted loss per share calculations	**425,243,000**	408,934,000

10 PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2026, the Group acquired assets at a cost of RMB21,830,000 (six months ended 30 June 2025: RMB6,719,000).

11 TRADE RECEIVABLES

An ageing analysis of the trade receivables as at the end of the Reporting Period, based on the invoice and net of loss allowance, is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade receivables		
Within 3 months	**22,413**	6,842
Over 3 months	**5,195**	–
	27,608	6,842

The trade receivables are non-interest bearing and normally settled within one year, and no provision for bad debt was made.

12 TRADE PAYABLES

An aging analysis of the trade payables as at the end of the Reporting Period is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade payables		
Within 1 year	**17,269**	24,239
Over 1 year	**3,759**	911
	21,028	25,150

Included in the trade payables were an amount due to related parties of RMB4,051,000 as at 30 June 2026 (as at 31 December 2025: RMB1,782,000), which was repayable within 1 year, representing credit terms similar to those offered by the related party to its major customers.

I. BUSINESS REVIEW

Overview

We are a medical device company dedicated to developing interventional products for the treatment of structural heart disease, with a strong focus on international expansion. We have developed a series of treatment solutions targeting different types of structural heart diseases and other related conditions and are actively developing and advancing the research, development and clinical transition of a number of new products, with a view to enriching our product portfolio, meeting diverse clinical needs globally, and injecting sustained momentum for the Company's long-term development.

Products and Pipeline

As of the date of this announcement, we have several products in various stages of commercialization and research and development, covering TTVR, TAVR and TMVr treatment and many other common fields of treatment on structural heart disease. The following diagram summarizes the progress of our product portfolio as of the date of this announcement:

Product Categories	Products	Pre-Clinical Stage	Clinical Stage[Note 1]	Registration	Commercialization[Note 2]
TTVR system	LuX-Valve Plus® ★				Approved in multiple countries and regions across Europe, the Middle East, and Asia-Pacific, and included in the Medical Device Catalog of Hong Kong-Macao Medicine and Equipment Connect
				NMPA approval: The application for the NMPA registration approval has been submitted and accepted, and is currently undergoing the registration review process	
			FDA approval: Enrollment for the pivotal clinical trial is underway		
	LuX-Valve®		Admitted to the green channel and having completed the patient follow-up of the multi-center registration clinical trial		
	LuX-Valve Pro™	Pre-Clinical Stage			
	LuX-Valve Ultra™	Pre-Clinical Stage			
TAVR system	Ken-Valve® ★				Approved in Chinese Mainland, Hong Kong and New Zealand
	Ken-Valve Pro® [Note 3]		Clinical trials are currently in preparation		
TMVr system	JensClip®			NMPA approval: The application for the NMPA registration approval has been submitted and accepted, and is currently undergoing the registration review process	
			CE certification: The application for CE certification has been submitted and accepted, and is currently undergoing the registration review process		
TMVR system	JensRelive®	Pre-Clinical Stage			
Technology/ Accessories	JeniGal® Anticalcification Technology				Approved in Chinese Mainland
	Catheter Sheath Products				Approved in Chinese Mainland
	Dry-valve Technology		Clinical trials are currently in preparation		
	Polymer Leaflet Technology	Pre-Clinical Stage			

★: Products with ★ are Core Products.

Note 1: Entering clinical stage is marked by the completion of first human trial.
Note 2: The point in time of expected commercialization is based on the obtaining of product registration certificate.
Note 3: Formerly known as KenFlex.

Our Products and Product Candidates

Tricuspid Valve Products

LuX-Valve Plus, our proprietary second-generation TTVR system, is designed for patients with severe tricuspid regurgitation and high surgical risk. LuX-Valve Plus, using a transvascular access approach, works by functionally replacing the patient's dysfunctional native tricuspid valve with a prosthetic valve implanted through a minimally invasive intervention without the need for conventional open-heart surgery. We expect the transvascular access path not only to effectively simplify the operation procedure with shorter device procedure time, smaller incisions and less damage to the heart tissue, but also to be used in a wider range of situations such as rare and complex anatomical structures. In addition, the delivery system of LuX-Valve Plus is multi-angle adjustable and steerable, allowing physicians to more conveniently adjust the release position and angle, and thereby further increasing the product's safety profile.

LuX-Valve Plus is the world's second approved transcatheter orthotopic tricuspid valve replacement device. LuX-Valve Plus has received registration approval in multiple countries and regions across Europe, the Middle East, and Asia-Pacific, and been included in the Medical Device Catalog of Hong Kong-Macao Medicine and Equipment Connect. We will continue to promote the application of our products in different regions worldwide, focusing on leveraging our EU MDR CE certification to penetrate key overseas markets, thereby further enhancing the Company's academic standing and influence in the world, and laying a solid foundation for the Company's globalization strategy.

LuX-Valve Plus has been selected for the Expert Panel Scientific Advice Pilot of the European Medicines Agency. With regard to the LuX-Valve series products, we sustain the global leadership of this series of products, comprehensively advancing the commercialisation of our core products across different countries and regions and providing support to any other subsequent key products through a diversified approach including conducting registration clinical trials and obtaining approvals in multiple countries and regions around the world, continuing our regional expansion for our business development, and establishing international collaborations.

The global multi-center clinical trial of the LuX-Valve Plus transcatheter tricuspid valve replacement system (the "**TRINITY study**") is a prospective, multi-center, single-arm clinical study designed to evaluate the safety of LuX-Valve Plus in patients with severe tricuspid regurgitation and at high surgical risk. The study enrolled 161 patients from 20 centers around the world, 18 of which are located in France, Germany, Spain, Denmark, and the United Kingdom. The TRINITY study has already entered the two-year follow-up phase.

In October 2025, the 6-month clinical follow-up results of the TRINITY study were officially released at the 2025 Transcatheter Cardiovascular Therapeutics (TCT 2025) conference held in San Francisco, USA. The results of the clinical study showed the device operation success rate was about 97%, and the average device operation time was 41.60±19.62 minutes, with the shortest device operating time being only 11 minutes. The safety results showed the composite adverse events rate at 6-month, as determined by the Clinical Events Committee (CEC) for the full analysis set plus the learning curve group, is 19.9%, which was relatively low. The efficacy results showed 6-month follow-up outcomes demonstrated that 94.4% of patients had no above moderate regurgitation; patients' cardiac function and quality of life were significantly improved. The 6-month clinical follow-up results of the TRINITY study demonstrated good safety and performance of LuX-Valve Plus, with continued improvement in the quality of patient's life and a low rate of safety events. For details, please refer to the announcement of the Company dated 29 October 2025.

In November 2025, the 6-month clinical follow-up results in large annulus patients of the TRINITY study were released at the PCR London Valves 2025 conference. In the TRINITY study, over 75% of patients used valve sizes of 55mm, 60mm, 65mm, and 70mm, and the average age of these large annulus patients (LAP) was 77.4 and the average Tri-Score was as high as 13.5%; 10.7% of patients exhibited 3+ (Severe) TR, 47.1% exhibited 4+ (Massive) TR, and 42.2% exhibited 5+ (Torrential) TR. The safety results showed that the 6-month follow-up outcomes demonstrated the composite adverse events rate of the LAP group (N=121) was 22.3%. The efficacy results showed the 6-month follow-up outcomes demonstrated that 93.5% of LAP had no above moderate tricuspid regurgitation; and patients' cardiac function and quality of life were significantly improved. The results of the TRINITY study demonstrate that it significantly improves regurgitation severity and markedly enhances the quality of life in patients with large annulus tricuspid regurgitation. It is expected to address the global unmet clinical need for effective treatment options for a large number of patients with large annulus tricuspid regurgitation. For details, please refer to the announcement of the Company dated 20 November 2025.

In May 2026, the twelve-month clinical follow-up results for large annulus patients of the TRINITY study were officially released at EuroPCR 2026. In the EU TRINITY study, over 75% of patients used valve sizes of 55mm, 60mm, 65mm, and 70mm, and the average age of these patients was 77 and the average Tri-Score was 13.6%; 9.7% of patients exhibited Severe TR, 47.8% exhibited Massive TR, and 42.5% exhibited Torrential TR. The efficacy results showed that in terms of improvement in the tricuspid regurgitation grade, 97.8% of LAP showed no above moderate regurgitation; in terms of New York Heart Association cardiac function improvement, 91.6% of LAP had their postoperative cardiac function improved to class I/II; and in terms of quality of life, the Kansas City Cardiomyopathy Questionnaire scores improved, on average, by approximately 17 points; in addition, the average improvement in 6-minute walking distance for LAP was approximately 43 meters. The safety results showed that the twelve-month follow-up outcomes demonstrated the composite adverse events rate of the LAP group (N=113) was 28.3%. The twelve-month clinical follow-up results show the excellent efficacy and safety of LuX-Valve Plus in LAP. For details, please refer to the announcement of the Company dated 21 May 2026.

FDA Clinical Trial and Registration

Significant progress has been made in the U.S. registration clinical trial and overseas application of LuX-Valve Plus. Patient enrollment for the U.S. LuX-Valve Plus Early Feasibility Study ("**EFS clinical study**") has been fully completed, the 30-day follow-up data and report of the EFS clinical study have been submitted to the FDA, and the project is currently in the one-year follow-up phase. The FDA had officially approved the application for an unconditional investigational device exemption (IDE) for the Pivotal Trial of LuX-Valve Plus, and the first batch of patient implantations has been successfully completed in the Pivotal Trial. We will continue to actively advance the Pivotal Trial process of LuX-Valve Plus, and strive to obtain FDA launching approval for this product as soon as possible.

LuX-Valve Plus was selected to participate in the FDA's Total Product Life Cycle Advisory Program ("**TAP**") pilot. The EFS clinical study for LuX-Valve Plus was certified as CMS Category B by the FDA and approved for inclusion in medical insurance coverage by the Centers for Medicare & Medicaid Services (CMS) of United States. The LuX-Valve Plus Pivotal Trial has also been certified as CMS Category B by FDA, eligible for CMS medicare reimbursement. These progress have laid a solid foundation for the subsequent smooth conduct of the Pivotal Trial and positively impact on the expedited regulatory process.

NMPA Clinical Trial and Registration

The NMPA multi-center registration clinical trial of LuX-Valve Plus in China has already entered the long-term follow-up phase, demonstrating excellent clinical follow-up data. The randomized controlled trials of optimized medical therapy of LuX-Valve Plus conducted in China has completed full subject enrollment, and the application for NMPA registration has been accepted and received feedback. It is currently in the registration review phase. We will actively advance the NMPA registration process of LuX-Valve Plus, and strive to obtain the NMPA registration certificate as soon as possible.

LuX-Valve, our proprietary first-generation TTVR system, is designed to treat patients with both severe tricuspid regurgitation and high surgical risk. LuX-Valve works by replacing the function of a patient's dysfunctional native tricuspid valve with a prosthetic valve implanted through a minimally invasive intervention without the need for conventional open-heart operation. LuX-Valve was admitted into the Special Examination for Innovative Medical Devices (the "**Green Channel**") by the NMPA in January 2019. We are currently in the process of active communication with the NMPA, and expect that an application for registration will be submitted to the NMPA for approval in due course.

LuX-Valve Pro is our next-generation TTVR system developed based on LuX-Valve Plus. To further enhance patient benefits and its usability, LuX-Valve Pro has undergone upgrades in the local structure and performance of the valve, incorporates dual-segment steering function for the delivery catheter, and optimizes the design of the knobs and operation of the delivery system. The product is expected to offer higher precision in valve implantation, better interventional experience, and greater benefit for more patients. LuX-Valve Pro is currently in the pre-clinical stage.

LuX-Valve Ultra is our next-generation TTVR system developed based on LuX-Valve Pro. New materials will be used for this Prosthetic Valve to enhance leaflet performance, reduce preparation time for valve operation, and improve interventional support efficiency. The delivery system features a variety of venous access options, and further reduces the catheter's outer diameter, thereby mitigating the risk of complications in narrow or small vein access. In addition, functional design will be refined to optimize the handle of the delivery system so as to enhance user experience and convenience for operators. The LuX-Valve Ultra is currently in the pre-clinical stage.

Aortic Valve Products

Ken-Valve, our proprietary first-generation TAVR system, is designed for the treatment of patients with severe aortic regurgitation or combined with aortic stenosis. The Ken-Valve features a multi-size stent platform, designed to address severe aortic regurgitation ("**AR**") or combined aortic stenosis ("**AS**"), thereby covering the majority of aortic valve pathologies. The valve employs anti-calcification treated bovine pericardial leaflets in a supra-annular design, achieving an optimal balance between large effective orifice area, long-term durability, and effective anti-thrombogenic properties. The integrated positioning components of Ken-Valve are engineered to resolve anatomical challenges, such as annular dilation and the lack of anatomical structures for anchoring in the sinus of Valsalva. These positioning components engage the native leaflets within the sinus, achieving coaptation alignment while generating radial clamping forces. This mechanism ensures stable anchoring and prevents coronary ostium obstruction caused by prosthetic valve interference. An anti-paravalvular leakage ("**PVL**") skirt integrated into the stent's anchoring zone significantly reduces post-procedural PVL risk. The delivery system incorporates active steerable function with a non-wire-controlled steering mechanism, enabling precise navigation. This innovation is projected to shorten the operator learning curve and improve procedural efficiency.

We have obtained relevant permits for the manufacture and sale of Ken-Valve in China, and commercial implantation procedures are conducted progressively at an accelerating pace nationwide. Ken-Valve obtained the registration approval from the New Zealand Medicines and Medical Devices Safety Authority in February 2026 and approval from Hong Kong Department of Health in June 2026. Building upon its current achievement in commercialisation, the Company will continue to strengthen the global market layout of Ken-Valve. For the domestic market, we will consistently solidify and expand our leading advantage to ensure a steady growth in sales and the implantation. For overseas markets, taking the approval in New Zealand and the first batch of commercial implantations as a springboard, we aim to transition our international operation from individual breakthroughs to full-scale rollout, thereby accelerating the full realisation of our global strategic objectives.

In April 2025, the one-year clinical follow-up data of Ken-Valve was released at the 6th China Structural Heart Disease Conference (CSHC 2025). The number of enrollment of this clinical study is ahead of similar products, with large patient demand and excellent efficacy. The average age of the enrolled patients was 70.31±5.50, and 99.3% of the patients were in NYHA cardiac function class III/IV. In addition, 61.97% of the patients in the study population had a moderate-to-severe frailty index, 80.85% of the patients had a 5-metre walk time of ≥6 seconds, and all were assessed to be unsuitable for operation by the surgical risk assessment, with the maximum diameter of the aortic annulus being 32mm. The clinical results showed that the average operating time of Ken-Valve was 8.70±8.85 minutes, the success rate of the device was 97.18% and the one-year all-cause mortality rate was merely 5.63%. From the moment of implantation of Ken-Valve to one year after the procedure, the percentage of patients with aortic regurgitation reduced to mild or less was 100%, and postoperative cardiac function and quality of life indicators had improved as compared with those before the procedure. The average effective orifice area (EOA) of the implanted valve was ≥ 1.90 cm^2, and the valves were functionally stable and performed well within one year after the procedure.

In November 2025, the one-year clinical follow-up data of Ken-Valve for patients with large annulus were released at PCR London Valves 2025. In the clinical study, over 45% of patients used valve sizes of 29mm, 31mm, and 33mm. The average age of this group of patients was 72 and the average STS score reached 5.60%. The clinical results showed that the device success rate of the full analysis set ("**FAS**") was 97.2%, among which the success rate of LAP was 93.8%; the average device operation time for the FAS was 8.70±8.85 minutes, among which the average device operation time for LAP was 8.23±4.60 minutes. The one-year clinical follow-up results of Ken-Valve for LAP showed that the product has outstanding safety and efficacy, with a significant improvement in symptomatic aortic regurgitation, a noticeable improvement in quality of life, and a low incidence of composite adverse events. For details, please refer to the announcement of the Company dated 20 November 2025.

Ken-Valve Pro, our proprietary next-generation TAVR (transfemoral) system, is used for the treatment of severe aortic regurgitation or combined with aortic stenosis. Major upgrades of Ken-Valve Pro have been made to valves and delivery systems. While reducing radial support and the impact on the conductive bundle branch, the valve is stably fixed and the pacemaker implantation rate is lowered, which is expected to improve the accuracy and stability of valve placement. Ken-Valve Pro is currently in the clinical trial preparation stage.

Mitral Valve Products

JensClip, our proprietary clip-based TMVr system, is designed to treat patients with severe mitral regurgitation. The JensClip system introduces an innovative self-locking design, providing secure leaflet fixation to maintain stable coaptation and locking, thus effectively reducing mitral regurgitation. Featuring a rhombic linkage mechanism, the valve clip enables enhanced shape adaptability during transvalvular navigation, facilitating smooth valve crossing. Its bidirectional retrievability significantly improves procedural safety. The device enables both simultaneous bilateral and selective unilateral leaflet capture to enhance procedural adaptability. An integrated detachment mechanism minimizes potential risks associated with multi-step detachment processes, effectively reducing accidental deployment errors and shortening procedural time. We have submitted the registration application for JensClip to the NMPA, which was accepted and is currently under review. We also formally submitted the registration application for CE certification, which is currently in the registration review phase. We are actively promoting domestic and international registration and approval processes.

In May 2025, the one-year clinical follow-up results of the JensClip were released at the EuroPCR 2025 in Paris, France. The study primarily evaluated the safety and efficacy of JensClip in application on patients with symptomatic degenerative mitral regurgitation (DMR) at high surgical risk. The study enrolled 114 patients from 18 centers in China. The clinical results showed that the technical success rate was 98%, and the average device operation time was 67.53±43.89 minutes. The average age of the patients was 71 years old. The safety indicators showed that all-cause mortality rate was merely 1.8%. The efficacy indicators showed that, in the one-year follow-up, 96.3% of patients had no above moderate regurgitation and patients' cardiac function and quality of life were significantly improved.

The globalization process of JensClip is also being actively advanced. As of the date of this announcement, a series of pre-commercial clinical implants of JensClip have been conducted overseas, with all procedures progressing smoothly and the product performance being excellent.

JensRelive, our proprietary TMVR (transfemoral) system, is designed to treat patients with severe mitral regurgitation. It works by replacing a patient's damaged native mitral valve without the need for conventional open-heart operation. JensRelive consists of a prosthetic mitral valve and a delivery catheter system. Our JensRelive uses a special anchoring design that facilitates valve fixation, prevents displacement and is expected to resolve issues such as outflow obstruction and PVL. In addition, JensRelive is equipped with multiple steerable functions, which are expected to improve the valve positioning accuracy and stability during deployment. As of the date of this announcement, we are in the process of conducting pre-clinical studies for JensRelive.

Platform Technology/Accessories

Catheter sheath products have received the product registration certificate from NMPA. The product is available in multiple sizes, which can effectively prevent jugular vein injury during operational manipulation.

JeniGal anti-calcification technology is currently applicable to all of the Company's commercial products and product candidates, aiming to effectively improve the anti-calcification function of the leaflets and reduce immunogenicity.

Dry valve technology is currently in the preparation stage of clinical trial and can be used in the Company's TAVR, TMVR or TTVR product candidates in the future. The Company continues to advance the research and development of dry valve technology to improve product's durablility, biocompatibility and ease of storage and transport through leaflet dehydration.

Polymer leaflet technology is currently in the pre-clinical stage and can be used in the Company's TAVR, TMVR or TTVR product candidates in the future. The Company is conducting the research and development of polymer leaflet technology, exploring the replacement of traditional biological leaflets with polymer materials, with a view to driving a materials revolution and enhancing the overall performance of products for structural heart disease.

Cautionary Statement as required by Rule 18A.08(3) of the Listing Rules: There is no assurance that we will ultimately develop, market and/or commercialize our Core Products or any other product candidates successfully.

Research and Development

Sustained technological innovation is the core element in maintaining our market competitiveness and the primary driving force behind the Company's long-term sustainable development. During the Reporting Period, the Company's R&D team accumulated extensive internationally advanced R&D experience through the technological development and international registration processes of its core products, significantly enhancing its professional technical capabilities and global perspective. To systematically institutionalize its technological expertise and optimize its R&D framework, the Company has established a number of specialized functional teams within its R&D organizational structure, enabling the efficient sharing, cross-pollination, and complementary leveraging of technical pathways, development experience, and resources across different product lines and R&D projects, thereby further improving its overall R&D efficiency and forward-looking technological planning capabilities. The Company has consistently adhered to the iterative development philosophy of "commercializing one generation, developing the next, and reserving future pipelines", continuously pursuing technological upgrades and product iterations around its core product portfolio. By pursuing constant technological optimization and innovative development, the Company ensures a long-term, leading competitive edge of its product matrix.

Meanwhile, the Company continues to enhance its systematized and platform-driven R&D capabilities, with a focus on establishing three core technology platforms: a new material development technology platform dedicated to the R&D of next-generation polymer biomaterials and material performance optimization, a simulation technology platform providing scientific validation support for R&D via numerical simulation and image-based modeling, and an AI robotics technology platform focused on precision, intelligence, and standardized innovations in interventional procedures. Building on its comprehensive platform-based R&D system, the Company continues to iteratively upgrade its existing product pipeline and actively advance the R&D of next-generation platform-based products, with emphasis on the development of new-generation iterative products such as Ken-Valve Pro, LuX-Valve Pro, and LuX-Valve Ultra etc.. In parallel, the Company is accelerating R&D tackling in core underlying technologies, including new polymer valve leaflet materials, aiming to optimize device structural design, enhance valve fatigue resistance and anti-calcification performance so as to simplify clinical procedural complexity, and expand the eligible patient population.

During the Reporting Period, the Company's iJensRobo robotic-assisted LuX-Valve Plus system successfully completed the world's first-in-human clinical trial in Hong Kong with favorable patient outcomes. This marks a major milestone breakthrough for the Company in the field of integrated innovation combining "interventional devices + intelligent robotics", further consolidating the Company's technological leadership in innovative treatments for structural heart disease. Looking ahead, the Company will remain laser-focused on clinical pain points and future clinical needs, leveraging its multi-dimensional and systematic technology portfolio to continuously incubate and launch innovative medical device products with global competitiveness, thereby laying a solid technological foundation for the Group's long-term, stable, and high-quality development.

Intellectual Property

As of the date of this announcement, we have:

- 434 patent applications in more than 20 countries or regions and have obtained 297 granted patents;

- 75 trademark registration applications in more than 38 countries or regions and have been granted 52 registered trademarks.

The Company possesses multiple high-quality patents protecting its core technologies, covering application scenarios and process improvements, with patent strategies aligned with technology life cycles. By establishing a patent matrix that encompasses both core technologies and peripheral applications, the Company has built a multi-tiered protection system. It has filed patent applications and obtained patent grants in major markets including the PRC, the United States, Europe, Australia, South America, and Japan, while formulating corresponding intellectual property defense strategies. In addition, we have developed a global trademark strategy and built a systematic competitive barrier for our worldwide operations through synergistic alignment of our trademark and patent strategies. In 2023, we established a Ningbo Municipal Trade Secrets Demonstration Site and obtained certification under the (GB/T 29490–2023) Intellectual Property Management System, underscoring our continuous efforts to enhance our intellectual property protection framework in support of global business expansion of the Company.

Manufacturing

The Group has established an annual capacity of over 10,000 units. Driven by enhanced production efficiency, the Company's large-scale delivery capability has further been strengthened, providing capacity assurance for the volume growth of its core products, the launch of new products, and the expansion of its global market presence. Our manufacturing facility is located in Ningbo, Zhejiang, the PRC, and along with two adjacent properties, occupies approximately 8,500 square meters. It is designed and built for manufacturing medical devices in compliance with GMP requirements with full manufacturing capability and ready for commercial-scale production. Our manufacturing center has obtained the manufacturing license issued by the NMPA and passed the on-site audit for EU CE MDR certification. We have full manufacturing capabilities, including production lines and related core technologies for stents, valves, and delivery systems, respectively. We continuously enhance process stability, address technical challenges, and improve the production capabilities to constantly increase production capacity and product yield rate. Meanwhile, we continuously upgrade workforce skills and operational synergy, vigorously reinforce the multi-skill training system for operational and technical staff. This has substantially boosted our production capacity to meet the growing commercial and clinical supply demands, effectively supporting the rapid expansion of our current business model. We adhere to lean manufacturing practices. Through refined cost control and strengthened supplier management, we optimize the cost structure while maintaining quality, thereby enhancing the market competitiveness of our products.

We strictly comply with the laws and regulations related to production quality. We have established an international quality control system in accordance with regulations and standards such as ISO13485, GMP of the NMPA, CE MDR, and MDSAP. Under such system, we manage our products from R&D to market launch so as to ensure the compliance, safety and effectiveness of our products throughout their life cycle. As of the date of this announcement, the Company has obtained ISO13485 certification, CE MDR certification, MDSAP certification, and the Production License for Medical Device in China, among other qualifications. We procured advanced manufacturing and inspection equipment and machinery from reputable suppliers and completed comprehensive commissioning and qualification steps to verify that the equipment and programs are installed according to the requisite specifications. We strictly monitor the procurement of raw materials, the production process, and the final delivery to ensure the quality, safety and effectiveness of the products.

Commercialization

The Company continued to accelerate the global commercialization of its product pipeline portfolio, steadily expanded clinical implantation coverage, and significantly increased its penetration in international markets. Leveraging our differentiated product positioning, we rapidly established a clear and distinct brand image, featuring stable performance and ease of operation of our products, which effectively helped surgeons develop consistent usage habits and deepened clinical adoption.

Our products in structural heart disease have demonstrated outstanding clinical advantages. Core products such as the LuX-Valve TTVR series and the Ken-Valve TAVR system are capable of addressing challenging anatomies, including large annuli and complex structures, while the JensClip TMVr system delivers remarkable clinical outcomes with its unique locking mechanism.

On a global scale, our products have achieved multiple clinical and commercial breakthroughs. Among them, LuX-Valve Plus has also made significant progress. It has been approved for inclusion in the Medical Device Catalog of Hong Kong-Macao Medicine and Equipment Connect, allowing for commercial clinical use in designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area. Meanwhile, as of the date of this announcement, it has obtained EU MDR CE certification and approval from the New Zealand Medicines and Medical Devices Safety Authority, marking its official entry into commercialization. In addition, the EU MDR CE certification process for JensClip is advancing steadily, and fee-based clinical implants continue to be performed across various regions worldwide.

In China, Ken-Valve has established a comprehensive regional distribution network and developed competitive sales strategies to adapt to market changes and accelerate commercial adoption. As of the date of this announcement, we have completed the listing process on procurement platforms in over 31 provincial-level administrative regions in China, with sales channels covering most cities nationwide and our products having been adopted by hundreds of hospitals. Meanwhile, Ken-Valve has obtained approvals from the New Zealand Medicines and Medical Devices Safety Authority and the Hong Kong Department of Health, and commercial initiatives have been intensified in both regions.

To further accelerate marketing and commercialization, the Company has established specialized local marketing teams in key global markets, focusing on core areas including product market access, procedural training, marketing and implantations. Furthermore, our treatment promotion and technical support team, leveraging its profound medical expertise and practical experience, is advancing the development of a globalized and standardized procedure training system through standardized clinical support and data feedback. Meanwhile, our marketing team is steadily expanding its global market presence, reinforcing channel development and brand promotion both domestically and internationally, and comprehensively enhancing the Company's international commercial operations and commercialization capabilities.

With regard to academic promotion, we leverage the clinical experience and academic influence of global key opinion leaders (KOL) to disseminate operative techniques to regional markets through diverse approaches, including academic conferences, live/recorded procedural demonstrations, and case study and discussions. Taking core medical centers as a pivot, we collaborate with regional and frontline centers to continuously enhance product awareness and expand target hospital coverage. Going forward, we will further deepen our academic partnerships with global KOL to reinforce procedural education and market penetration.

To accelerate the education and adoption of multiple innovative procedures, we have continuously enhanced our internal and external training system to deliver professional, systematic and full-process training covering product characteristics, operative techniques, imaging applications, perioperative management and complex case handling, thereby accelerating the efficient adoption of procedural education. We have built an "online+offline" integrated academic education platform centered on the "Jenscare Academy (健世學苑)". By linking to multi-channel digital academic media and systematically advancing education on product portfolio, we continue to strengthen our brand's academic influence, drive standardized treatment promotion, and enhance the clinical adoption rate in hospitals.

Specific online measures include:

- "HeartShare Insight (健享心聲)" online activities were regularly held to focus on the review of challenging surgical cases and the breakdown of core techniques, providing surgeons with a platform for in-depth learning and exchange;

- Leveraging the WeChat official account column of "Valve-ness ValveLearn Hub (瓣知健學)", we provide timely updates on progress and industry trends in the field of transcatheter valve intervention;

- We simultaneously advance the offline training sessions of "ValveCare Journey (健行千里)", establishing a three-level training system of "Theory in Depth, Live Demonstration, Simulated Practice" to comprehensively promote our product portfolio and standardized operative techniques, thereby empowering clinical practice.

In 2026, we have been invited to participate in a number of both domestic and overseas high-profile academic conferences in the field of structural heart diseases, including New York Valves 2026, EuroPCR 2026, CSI Frankfurt 2026, TCT LATAM 2026, Spanish Tricuspid Summit 2026, Spanish CSC Structural 2026, Sydney Valves 2026, PCR Tricuspid Focus Group 2026, Riyadh Valves 2026, Italian JIM-GISE 2026, the 20th Oriental Congress of Cardiology (OCC 2026), Transcatheter Atrioventricular Valve Repair and Replacement Summit (TAVR²S) 2026, China Valve (Hangzhou) Conference 2026, International Minimally Invasive Valve Summit Forum 2026, Beijing Valves 2026, Beijing Structural Heart Disease Surgery Forum 2026, and HCIC 2026. We will continue to participate in international and domestic top-tier academic exchanges to further consolidate the brand influence of the Company, enhance global expert recognition of our products, facilitate the market penetration of our procedures, and lay a solid foundation for the marketing and long-term commercial development of the Company's products.

II. FINANCIAL REVIEW

Revenue

During the Reporting Period, our revenue was mainly derived from the sale of interventional products for the treatment of structural heart disease.

During the Reporting Period, our revenue was RMB64.1 million (six months ended 30 June 2025: RMB13.4 million), mainly due to increased sales volume as a result of the continued commercialization of our interventional products for the treatment of structural heart diseases.

During the Reporting Period, revenue from Chinese Mainland and overseas amounted to RMB34.6 million and RMB29.5 million, respectively, with overseas revenue accounting for 46.0%.

Cost of Sales

During the Reporting Period, our cost of sales was mainly related to the production of interventional products for the treatment of structural heart diseases. Our cost of sales amounted to RMB8.7 million (six months ended 30 June 2025: RMB1.6 million), mainly due to the increase in costs of raw materials, staff costs and manufacturing costs as a result of the increase in sales volume.

Gross Profit and Gross Profit Margin

During the Reporting Period, our gross profit was RMB55.5 million (six months ended 30 June 2025: RMB11.8 million), in line with the increase in revenue. Gross profit margin is calculated as gross profit which was divided by revenue multiplied by 100%. Our gross profit margin for the Reporting Period was 86.5%.

Selling and Distribution Expenses

During the Reporting Period, our selling and distribution expenses were RMB22.5 million, mainly attributable to the continuous increase in the frequency and scale of our marketing campaigns to expand our global footprint.

Other Income and Gains

Our other income and gains primarily consist of (i) gains on financial assets at fair value through profit or loss, representing the realized and unrealized gains from wealth management products; (ii) government grants, primarily including subsidies received from the local governments to support our R&D activities and business operations; (iii) interest income from bank deposits; and (iv) others. Our other income and gains decreased from RMB12.1 million for the six months ended 30 June 2025 to RMB9.8 million for the six months ended 30 June 2026. The decrease was primarily attributable to the decrease in interest income from bank deposits and gains on financial assets at fair value through profit or loss.

R&D Expenses

Our R&D expenses primarily consist of (i) share-based compensation expenses; (ii) staff costs, including salaries, bonus and welfare for R&D personnel; (iii) costs of raw materials and consumables used for R&D of our product candidates; and (iv) third-party contracting costs, primarily including payments to contract research organizations, clinical trial sites, and other medical institutions and testing fees incurred for preclinical studies and clinical trials.

Our R&D expenses decreased from RMB88.9 million for the six months ended 30 June 2025 to RMB52.6 million for the six months ended 30 June 2026. The decrease in our R&D expenses was primarily attributable to the decrease of RMB34.2 million in share-based compensation expenses and third-party contracting costs.

The following table sets forth a breakdown of our R&D expenses in absolute amounts for the periods indicated:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Share-based compensation expenses	**9,806**	36,238
Staff costs	**15,908**	15,622
Costs of raw materials and consumables used	**6,856**	6,755
Third-party contracting costs	**11,117**	18,877
Depreciation and amortization	**2,769**	2,761
Others	**6,120**	8,632
Total	**52,576**	88,885

Administrative Expenses

Our administrative expenses primarily consist of (i) share-based compensation expenses; (ii) staff costs, including salaries, bonus and welfare for administrative personnel; (iii) professional service fees incurred primarily in relation to recruitment, legal and accounting services; (iv) depreciation and amortization; (v) traveling and transportation expenses; and (vi) others.

Our administrative expenses decreased from RMB57.4 million for the six months ended 30 June 2025 to RMB33.6 million for the six months ended 30 June 2026. The decrease in our administrative expenses was primarily attributable to the decrease in share-based compensation expenses, partially offset by the increase in depreciation and amortization.

The following table sets forth a breakdown of our administrative expenses for the periods indicated:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Share-based compensation expenses	**8,694**	35,448
Staff costs	**9,271**	9,855
Professional service fees	**1,677**	3,668
Depreciation and amortization	**6,193**	2,076
Traveling and transportation expenses	**1,209**	1,433
Utilities and office expenses	**926**	935
Others	**5,656**	4,018
Total	**33,626**	57,433

Other Expenses

Our other expenses mainly consist of: (i) loss on disposals of property, plant and equipment; (ii) impairment of property, plant and equipment; (iii) cooperation termination payments; (iv) the net exchange loss in respect of bank balances and cash denominated in foreign currency; (v) donations expense; and (vi) others.

Our other expenses decreased to RMB5.2 million for the six months ended 30 June 2026. The decrease was primarily attributable to the absence of cooperation terminations during the Reporting Period.

Reversal of Impairment Losses on Financial Assets, Net

Our reversal of impairment losses on financial assets increased from RMB321,000 for the six months ended 30 June 2025 to RMB427,000 for the six months ended 30 June 2026. The increase was primarily attributable to the reversal of impairment loss on other receivables.

Finance Costs

Our finance costs mainly consist of lease liabilities and other borrowings.

Our finance costs increased from RMB138,000 for the six months ended 30 June 2025 to RMB669,000 for the six months ended 30 June 2026. The increase was primarily attributable to the increase in interest on bank and other loans.

Income Tax Expenses

We did not incur any income tax expenses during the Reporting Period.

Loss for the Period and Non-IFRS Measures

Based on the factors described above, our net losses decreased from RMB170.3 million for the six months ended 30 June 2025 to RMB48.8 million for the six months ended 30 June 2026.

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Loss for the period	**(48,763)**	(170,289)
Add:		
Share-based compensation expenses	**19,021**	71,751
Foreign exchange differences, net	**5,156**	6,782
Adjusted non-IFRS loss for the period	**(24,586)**	(91,756)

To supplement the Group's consolidated financial statements presented in accordance with IFRS, we use adjusted non-IFRS loss for the period as an additional financial measure. The Company believes that the adjusted non-IFRS financial measure provides useful information to investors and other parties in understanding and evaluating the Group's consolidated statement of profit or loss. However, the Company's adjusted non-IFRS loss for the period cannot and should not be used in isolation or considered as a substitute for the financial information prepared and presented in accordance with IFRS. Shareholders and potential investors should not consider the Company's adjusted non-IFRS measures in isolation, or as a substitute for the results prepared in accordance with IFRS.

Working Capital

We primarily allocate cash to the ongoing commercialization of our interventional products for the treatment of structural heart diseases, research and development of product candidates, and capital expenditures.

During the Reporting Period, our cash and cash equivalents, bank term deposits and wealth management products totalled approximately RMB488.0 million.

Our net cash used in investing activities was RMB8.8 million during the Reporting Period, primarily attributable to purchases of items of property, plant and equipment, partially offset by cash generated from investment income from disposal of financial assets at fair value through profit or loss.

Our net cash used in financing activities was RMB11.6 million during the Reporting Period, primarily due to repayment of bank loans.

Our net current assets decreased from RMB514.7 million as of 31 December 2025 to RMB470.8 million as of 30 June 2026, primarily attributable to R&D expenses, selling expenses, and administrative expenses incurred during the Reporting Period.

Capital Expenditures

We regularly incur capital expenditures to expand our operations, upgrade our facilities, enhance our development capabilities and improve our operating efficiency. Our capital expenditures primarily consisted of expenditures on properties, machinery and office equipment. We expect the main sources of funding for capital expenditures in 2026 to be from bank and other borrowings, net proceeds from the Global Offering, and capital contributions from our Shareholders.

Our capital expenditures increased from RMB6.0 million for the six months ended 30 June 2025 to RMB16.2 million for the Reporting Period. The increase was primarily attributable to an increase in capital expenditures on property, plant and equipment.

Key Financial Ratios

The following table sets forth the key financial ratios as at the dates indicated:

	As of 30 June	
	2026	2025
Current ratio[(1)]	**6.98**	6.77
Quick ratio[(2)]	**6.44**	6.39
Gearing ratio[(3)]	**12.8%**	11.6%

Notes:

(1) Current ratio is calculated based on total current assets divided by total current liabilities.

(2) Quick ratio is calculated based on total current assets less inventories divided by total current liabilities.

(3) Gearing ratio is calculated based on total liabilities divided by total assets multiplied by 100%.

Indebtedness

As of 30 June 2026, we had total bank and other borrowings of RMB37.2 million as compared to RMB43.8 million as of 31 December 2025. All of these borrowings bear fixed interest rate, with approximately RMB27.9 million due in more than one year and RMB9.3 million due within one year.

Our lease liabilities decreased from RMB3.6 million as of 31 December 2025 to RMB2.5 million as of 30 June 2026, primarily attributable to repayment of lease payment.

Pledge of Assets

As of 30 June 2026, buildings with a carrying amount of RMB163.9 million and leasehold land with a carrying amount of RMB23.6 million were pledged to secure the bank borrowings of RMB32.6 million.

Contingent Liabilities

As of 30 June 2026, we did not have any material contingent liabilities.

Significant Investments, Material Acquisitions and Disposals

During the Reporting Period, the Group did not hold any significant investments and we did not conduct any material acquisitions or disposals. Save as disclosed above, the Group does not have any specific plan on material investments or capital assets as of the date of this announcement.

Foreign Exchange Exposure

During the Reporting Period, we mainly operated in China and a majority of our transactions were settled in RMB, the functional currency of our Company. We are exposed to foreign currency risk mainly arising from exchange rate fluctuations of U.S. dollars against RMB. We currently do not have a foreign currency hedging policy. However, our management monitors foreign exchange exposure and will consider appropriate hedging measures in the future should the need arise.

Material Litigation

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group as of 30 June 2026.

HUMAN RESOURCES

To support long-term operations of its international business, the Company continues to advance its localized talent deployment across multiple regions globally, building a regional operational framework closely aligned with clinical needs, market access, and commercialization. This will enhance its overseas market insight, decision-making responsiveness, and execution efficiency. As of 30 June 2026, the Group had 225 employees in total, with whom the Group enters into contracts with its employees, in which clearly stipulate, among others, contract terms, remuneration, bonuses, employee benefits, confidentiality obligations, non-competition restrictions, and discharge and termination of the contract in compliance with relevant laws and regulations. The Group enrols its employees in social security and mandatory savings schemes (if any) and contributes the corresponding funds in full as required by local regulatory authorities, thereby fulfilling its statutory obligations in various regions to safeguard employees' rights and interests.

In terms of talent recruitment, the Group comprehensively evaluates the candidates based on a number of factors, including work experience, educational background and the requirements of relevant position, to select the best-suited candidates. To enhance our talent attraction, we provide competitive remuneration packages, a variety of incentive schemes, and comprehensive fringe benefits packages. Concurrently, through a combination of internal and external training programs, we provide continuing training for management members and all employees. These training programs cover various areas including product knowledge, project development, and team building, thereby continuously enhancing the expertise and overall competence of the employees.

Furthermore, the Group has established a regular performance appraisal mechanism, with the appraisal results being used as a key basis for remuneration adjustments, promotions and career development planning. We believe that a competitive benefits package, positive work environment and ample career development opportunities will contribute to fostering harmonious and stable labor relations, thereby ensuring the overall stability of our workforce.

Our Company has adopted the Employee Incentive Plans on 30 October 2020 and 27 April 2021 (details of which are set forth in the section headed "Employee Incentive Plans" in the Company's 2025 Annual Report, in the Company's circular dated 6 December 2022, and in our Prospectus). The Company has also adopted the H Share Scheme on 15 December 2023 (details of which are set out in the section headed "The H Share Scheme" of the Company's 2023 Annual Report and the circular of the Company dated 28 November 2023).

USE OF NET PROCEEDS FROM THE GLOBAL OFFERING

On 10 October 2022, the Company was successfully listed on the Stock Exchange. The net proceeds received by the Group from the Global Offering (after deducting underwriting fees and relevant expenses) amounted to approximately HK$206.4 million.

On 22 May 2025, the change in the use of the net proceeds from the Global Offering was approved by the Shareholders by way of an ordinary resolution at the annual general meeting of the Company. For details, please refer to the announcements of the Company dated 21 March 2025 and 22 May 2025, and the circular of the Company dated 23 April 2025.

The change to the intended use of the net proceeds from the Global Offering and its expected timeline for full utilisation is based on the best estimation of future market conditions made by the Company and subject to changes in accordance with our actual business operation.

The table below sets out the planned applications of the net proceeds from the Global Offering and actual usage as at 30 June 2026:

Business objective as stated in the Prospectus	Percentage of total net proceeds	Allocation of net proceeds *(HK$ million)*	Unutilised net proceeds as of 31 December 2024 *(HK$ million)*	Revised business objective	Revised allocation of unutilised net proceeds *(HK$ million)*	Unutilised net proceeds as of 31 December 2025 *(HK$ million)*	Utilised net proceeds during the Reporting Period *(HK$ million)*	Unutilised net proceeds as of 30 June 2026 *(HK$ million)*	Expected timeline for full utilisation of unutilised net proceeds
To fund the R&D, manufacturing and commercialisation of LuX-Valve and Ken-Valve	65.0%	134.1	119.7	To fund the R&D, manufacturing and commercialisation of LuX-Valve, LuX-Valve Plus and Ken-Valve	129.5	104.9	17.5	87.4	By 30 June 2028
For use relating to LuX-Valve	33.3%	68.7	56.7	For use relating to LuX-Valve and LuX-Valve Plus	77.5	65.8	9.8	56.0	By 30 June 2028
For use relating to Ken-Valve	31.7%	65.4	63.0	For use relating to Ken-Valve	52.0	39.1	7.7	31.4	By 30 June 2028
To fund the R&D, clinical trials and product registration of other product candidates in our pipeline, including LuX-Valve Plus, KenFlex and mitral valve products	25.0%	51.6	25.3	To fund the R&D, clinical trials and product registration of other product candidates in our pipeline, including KenFlex and JensClip	15.5	9.8	8.5	1.3	By 30 June 2028
For use relating to LuX-Valve Plus	17.0%	35.0	16.3	–	–	–	–	–	–
For use relating to KenFlex	4.0%	8.3	7.7	For use relating to KenFlex and Transcatheter Aortic Valve Products	2.7	1.3	–	1.3	By 30 June 2028
For use relating to mitral valve products	4.0%	8.3	1.3	For use relating to JensClip and mitral valve product	12.8	8.5	8.5	–	By 30 June 2028
Working capital and general corporate purposes	10.0%	20.7	9.9	Working capital and general corporate purposes	9.9	9.0	2.9	6.1	By 31 December 2027
Total	100%	206.4	154.9		154.9	123.7	28.9	94.8	

Note: KenFlex is now known as Ken-Valve Pro.

Save as disclosed, there are no other changes to the intended use of the net proceeds from the Global Offering as of the date of this announcement.

INTERIM DIVIDEND

The Board did not recommend the payment of an interim dividend for the Reporting Period (for the six months ended 30 June 2025: Nil).

IMPORTANT EVENTS AFTER THE REPORTING PERIOD

Save as disclosed in this announcement, there is no material subsequent event undertaken by the Company or by the Group after the Reporting Period and up to the date of this announcement.

CORPORATE GOVERNANCE PRACTICES

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code contained in Appendix C1 to the Listing Rules as its own code of corporate governance. During the Reporting Period, the Company has fully complied with all applicable code provisions of the CG Code.

The balance of power and authority is ensured by the operation of our Board and our senior management, which comprises experienced and visionary individuals. Our Board currently comprises one executive Director, five non-executive Directors and three independent non-executive Directors, and therefore has a strong independence element in its composition. The Board will closely monitor to ensure that there is a diverse set of skills and experiences that are relevant to the Company's strategic objectives and that there are no significant gaps in its collective expertise, thereby maintaining a Board skills matrix. The Board will also conduct regular evaluation of the Board's performance from time to time and to continue to review the effectiveness of the corporate governance structure of the Group to ensure compliance with the CG Code.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code contained in Appendix C3 to the Listing Rules as its own code of conduct regarding securities transactions by the Directors. Having made specific enquiries with all Directors, each of them has confirmed that he/she has fully complied with the Model Code during the Reporting Period. As required by the Company, relevant officers and employees of the Company are also bound by the Model Code, which prohibits them from dealing in securities of the Company at any time when he/she possesses inside information in relation to those securities. The Company was not aware of any non-compliance with the Model Code by the relevant officers and employees who are likely to possess inside information of the Company.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale or transfer of treasury shares (as defined in the Listing Rules)). The Company does not have any treasury shares (as defined in the Listing Rules) as at 30 June 2026.

REVIEW OF INTERIM RESULTS BY THE AUDIT COMMITTEE

The Board has established an Audit Committee which comprises three independent non-executive Directors, namely Ms. DU Jiliu, Dr. LIN Shoukang and Dr. MEI Lehe. Ms. DU Jiliu serves as the chairperson of the Audit Committee, who has the professional qualification and experience in financial matters in compliance with the requirements of the Listing Rules. The primary duties of the Audit Committee are to provide independent advice on the Company's financial reporting process, internal control and risk management system, oversee the audit process and perform other duties and responsibilities as assigned by the Board.

The Audit Committee, together with the management of the Company, has considered and reviewed the Group's interim results for the Reporting Period and the accounting principles and policies adopted by the Company, and discussed internal control and financial reporting matters (including the review of the interim condensed consolidated financial statements of the Group for the six months ended 30 June 2026) of the Group. It is of the view that the interim results of the Group are prepared in accordance with applicable accounting standards, rules and regulations and appropriate disclosures have been duly made. There is no disagreement between the Board and the Audit Committee regarding the accounting treatment adopted by the Company. The interim results have not been reviewed by the external auditor of the Company.

PUBLICATION OF INTERIM RESULTS AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (https://www.hkexnews.hk) and the Company (https://www.jenscare.com), respectively. The 2026 interim report of the Company containing all the information required by the Listing Rules will be dispatched to the Shareholders who requested printed copies and will be published on the respective websites of the Stock Exchange and the Company on or before the end of September.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings.

"Audit Committee"	the audit committee of the Board
"Board of Directors" or "Board"	the board of Directors
"CE certification"	Conformité Européenne, an administrative marking that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA)
"CG Code"	the "Corporate Governance Code" as contained in Appendix C1 to the Listing Rules
"China" or the "PRC"	the People's Republic of China, which, for the purpose of this announcement and for geographical reference only, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan, the PRC
"Company" or"our Company"	Jenscare Scientific Co., Ltd. (寧波健世科技股份有限公司), a joint stock company incorporated in the PRC with limited liability on 23 March 2021, whose H Shares are listed on the main board of the Stock Exchange (stock code: 9877)
"Core Product(s)"	LuX-Valve Plus and Ken-Valve, the designated"core products" as defined under Chapter 18A of the Listing Rules
"Director(s)"	the directors of the Company or any one of them
"Domestic Share(s)"	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in RMB and are unlisted Shares which are currently not listed or traded in any stock exchange
"FDA"	Food and Drug Administration in United States
"Global Offering"	the global offering of the H Shares, details of which are set forth in the Prospectus
"Group", "our Group","our", "we", or "us"	the Company and all of its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it

"H Shares"	overseas listed foreign invested ordinary share(s) in the ordinary share capital of our Company, with a nominal value of RMB1.00 each, which are to be subscribed for and traded in Hong Kong dollars and which are listed on the Stock Exchange
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong dollars","HK dollars" or "HK$"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange (as amended, supplemented or otherwise modified from time to time)
"Model Code"	the "Model Code for Securities Transactions by Directors of Listed Issuers" set out in Appendix C3 to the Listing Rules
"NMPA"	the National Medical Product Administration of the PRC* (中國國家藥品監督管理局), successor to the China Food and Drug Administration or CFDA (國家食品藥品監督管理總局)
"Prospectus"	the prospectus of the Company dated 23 September 2022
"R&D"	research and development
"Reporting Period"	the six months ended 30 June 2026
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"Share(s)"	ordinary share(s) in the share capital of our Company with a nominal value of RMB1.00 each, comprising Unlisted Shares and H Shares
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"treasury shares"	Save as used in the Financial Statements, has the meaning ascribed to it under the Listing Rules as amended from time to time
"United States" or "U.S."	the United States of America, its territories, its possessions and all areas subject to its jurisdiction

"Unlisted Foreign Share(s)"	ordinary share(s) issued by the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid for in currency other than RMB by foreign investors and are not listed on the Stock Exchange
"Unlisted Share(s)"	Domestic Shares and Unlisted Foreign Shares
"%"	per cent

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, 31 August 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. PAN Fei, as an executive Director; Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing, as non-executive Directors; and Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe, as independent non-executive Directors.